DOP2022000137A - Compuesto de piridazinil-tiazolcarboxamida - Google Patents
Compuesto de piridazinil-tiazolcarboxamidaInfo
- Publication number
- DOP2022000137A DOP2022000137A DO2022000137A DO2022000137A DOP2022000137A DO P2022000137 A DOP2022000137 A DO P2022000137A DO 2022000137 A DO2022000137 A DO 2022000137A DO 2022000137 A DO2022000137 A DO 2022000137A DO P2022000137 A DOP2022000137 A DO P2022000137A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treatment
- cancer
- compound
- antibodies
- pyridazinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1. Los inventores de la presente han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1 y descubrieron que un compuesto de piridazinil- tiazolcarboxamida tiene efecto inhibitorio sobre DGK ¿ (DGKzeta), lo que da lugar a la consecución de la presente invención. El compuesto de piridazinil- tiazolcarboxamida de la presente invención tiene efecto inhibitorio sobre DGK ¿ y puede usarse como agente terapéutico para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019233673 | 2019-12-25 | ||
PCT/JP2020/048337 WO2021132422A1 (ja) | 2019-12-25 | 2020-12-24 | ピリダジニルチアアゾールカルボキシアミド化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000137A true DOP2022000137A (es) | 2022-11-30 |
Family
ID=76574296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000137A DOP2022000137A (es) | 2019-12-25 | 2022-06-24 | Compuesto de piridazinil-tiazolcarboxamida |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220315603A1 (es) |
EP (1) | EP4083038A4 (es) |
JP (1) | JP6948659B1 (es) |
KR (1) | KR20220119702A (es) |
CN (2) | CN115626919A (es) |
AR (1) | AR120896A1 (es) |
AU (1) | AU2020413997A1 (es) |
BR (1) | BR112022012637A2 (es) |
CA (1) | CA3165889A1 (es) |
CL (1) | CL2022001752A1 (es) |
CO (1) | CO2022009124A2 (es) |
CR (1) | CR20220328A (es) |
DO (1) | DOP2022000137A (es) |
EC (1) | ECSP22057324A (es) |
IL (1) | IL294136A (es) |
JO (1) | JOP20220163A1 (es) |
MX (1) | MX2022007993A (es) |
PE (1) | PE20230163A1 (es) |
TW (1) | TW202136275A (es) |
WO (1) | WO2021132422A1 (es) |
ZA (1) | ZA202207543B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
MX2022013388A (es) | 2020-04-24 | 2022-11-30 | Bayer Ag | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune. |
IL303209A (en) | 2020-11-30 | 2023-07-01 | Astellas Pharma Inc | A heteroaryl carboxamide compound |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CN114621214B (zh) * | 2022-04-25 | 2024-04-26 | 宜春学院 | 一种抗菌席夫碱n-酰化物及其制备方法和应用 |
WO2024108100A1 (en) * | 2022-11-18 | 2024-05-23 | Incyte Corporation | Heteroaryl fluoroalkenes as dgk inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
AU2006208045B2 (en) * | 2005-01-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
AU2007208225B2 (en) * | 2006-01-25 | 2013-05-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
AU2007314342B2 (en) | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
SI3814348T1 (sl) * | 2018-06-27 | 2023-10-30 | Bristol-Myers Squibb Company | Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic |
AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
IL303209A (en) * | 2020-11-30 | 2023-07-01 | Astellas Pharma Inc | A heteroaryl carboxamide compound |
-
2020
- 2020-12-23 AR ARP200103641A patent/AR120896A1/es unknown
- 2020-12-24 AU AU2020413997A patent/AU2020413997A1/en active Pending
- 2020-12-24 PE PE2022001161A patent/PE20230163A1/es unknown
- 2020-12-24 JP JP2021531562A patent/JP6948659B1/ja active Active
- 2020-12-24 JO JOP/2022/0163A patent/JOP20220163A1/ar unknown
- 2020-12-24 KR KR1020227025714A patent/KR20220119702A/ko unknown
- 2020-12-24 BR BR112022012637A patent/BR112022012637A2/pt unknown
- 2020-12-24 US US17/427,426 patent/US20220315603A1/en active Pending
- 2020-12-24 CR CR20220328A patent/CR20220328A/es unknown
- 2020-12-24 MX MX2022007993A patent/MX2022007993A/es unknown
- 2020-12-24 TW TW109146029A patent/TW202136275A/zh unknown
- 2020-12-24 EP EP20906466.6A patent/EP4083038A4/en active Pending
- 2020-12-24 IL IL294136A patent/IL294136A/en unknown
- 2020-12-24 CN CN202211308277.1A patent/CN115626919A/zh active Pending
- 2020-12-24 CA CA3165889A patent/CA3165889A1/en active Pending
- 2020-12-24 CN CN202080011114.XA patent/CN113365994A/zh active Pending
- 2020-12-24 WO PCT/JP2020/048337 patent/WO2021132422A1/ja active Application Filing
-
2022
- 2022-06-24 DO DO2022000137A patent/DOP2022000137A/es unknown
- 2022-06-24 CL CL2022001752A patent/CL2022001752A1/es unknown
- 2022-06-30 CO CONC2022/0009124A patent/CO2022009124A2/es unknown
- 2022-07-07 ZA ZA2022/07543A patent/ZA202207543B/en unknown
- 2022-07-21 EC ECSENADI202257324A patent/ECSP22057324A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP22057324A (es) | 2022-08-31 |
CO2022009124A2 (es) | 2022-07-19 |
MX2022007993A (es) | 2022-07-21 |
CN113365994A (zh) | 2021-09-07 |
JOP20220163A1 (ar) | 2023-01-30 |
CL2022001752A1 (es) | 2023-03-10 |
JP6948659B1 (ja) | 2021-10-13 |
TW202136275A (zh) | 2021-10-01 |
AU2020413997A1 (en) | 2022-06-09 |
CA3165889A1 (en) | 2021-07-01 |
KR20220119702A (ko) | 2022-08-30 |
CN115626919A (zh) | 2023-01-20 |
US20220315603A1 (en) | 2022-10-06 |
CN115590854A (zh) | 2023-01-13 |
JPWO2021132422A1 (ja) | 2021-12-23 |
PE20230163A1 (es) | 2023-02-01 |
ZA202207543B (en) | 2023-12-20 |
WO2021132422A1 (ja) | 2021-07-01 |
BR112022012637A2 (pt) | 2022-09-06 |
EP4083038A1 (en) | 2022-11-02 |
AR120896A1 (es) | 2022-03-30 |
IL294136A (en) | 2022-08-01 |
CR20220328A (es) | 2022-08-30 |
EP4083038A4 (en) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000137A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
CO2019008487A2 (es) | Compuesto de quinazolina | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
DOP2023000107A (es) | Compuesto de heteroarilcarboxamida | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
CR20150523A (es) | Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas | |
CL2016000837A1 (es) | “formas isoméricas especificas del 7-hidroxi-6,8-dioxo-n-(2,4,6-triflúorobencil)-1,2,3,4,6,8,12,12a-octahidro-1,4-metanodipirido[1,2-a:1’,2’-d]pirazina-9-carboxamida; composición farmacéutica que los comprende; y su uso en el tratamiento de una infección por vih”. | |
CL2019003589A1 (es) | Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer. | |
AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
BR112019004496A2 (pt) | estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
MX2022005132A (es) | Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1. | |
CO2018008445A2 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca | |
NI202000031A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
BR112019000240A2 (pt) | composições farmacêuticas | |
BR112022022713A2 (pt) | Dosagem e administração de anticorpo anti-ctla-4 ativável |